Roche's Avastin Fails in Early-Stage Colon Cancer Study

Roche's top-selling cancer-fighting drug Avastin has hit another roadblock in testing. In a Phase III study, Avastin failed to improve disease-free survival in early-stage colon cancer patients, the pharmaceutical giant reported.

Roche Announces Cost-Cutting Plan

Giant Swiss pharmaceutical company Roche has outlined a cost-cutting plan to help it offset pricing pressures in the U.S. and Europe, and following several setbacks in its late-stage research pipeline.

Roche Strikes $1.1 Billion Deal With Aileron

Swiss pharmaceutical giant Roche has struck a deal with Aileron Therapeutics worth up to $1.1 billion to gain access to a new class of drugs called stapled peptide therapeutics. This could yield new ways to attack hard-to-reach disease targets.

Amylin Shares Jump as Roche Delays Diabetes Drug

Pharmaceutical giant Roche said Friday that it would delay an FDA filing for its new diabetes drug for 12 to 18 months due to safety concerns. The beneficiary of Roche's misfortune is rival Amylin, which now jumps ahead in the race to get first approval of a once-weekly injectable type 2 diabetes drug.

Roche Sales Grow on Cancer Drug Demand

Roche shares climbed nearly 2% Thursday after the Swiss drugmaker posted first-quarter sales that rose 6% to 12.2 billion Swiss francs ($11.61 billion), thanks to strong demand for key cancer drugs. The results beat the average sales forecast.

Roche Diabetes Drug Makes Waves

The U.S. diabetes drug market just got a little more competitive. Swiss drugmaker Roche (RHHBY) said Wednesday an experimental medicine in late-stage development works better in treating type 2 diabetes than Merck (MRK) Januvia, according to a clinical study.

Genentech's great deal

Roche will finally buy Genentech (DNA) after months of fighting over a price for the acquisition. According to The Wall Street Journal (subscription...